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Relevance and Contribution to Literature: This study was designed to add to the body of knowledge gained through the original 
Asheville Project studies, and to address some of the limitations of the earlier studies. 
Scalability.  Since the original Asheville Project publications there have been some successful replications, however, there is a need 
to broaden the geographic scope and increase the size of the study population. 
Study Design.  Previous studies were limited to pre-post, self-as-control design.  We added a control group.   
Model improvement.  We were able to incorporate an electronic record of care. This allows incorporation of medical and 
prescription claims, ease of documentation, improved data capture, reporting, standardization of care, identification of deficiencies 
in care, and communication with other health care providers.  This enhancement may be worthy of more comment than we devoted 
to it , however, we didn’t want to detract from the main goal of the study, and we wanted to avoid any hint of commercialization on 
the part of the organization that provided the electronic record. 
Relevance to profession.  We sincerely hope the relevance goes beyond the profession of pharmacy and that it reinforces the 
message that the profession of pharmacy offers real solutions to rising health care costs in the U.S. 
 
Abstract 
Background:  A large (12,374 financial cohort, 2,623 clinical cohort), multi-year (4 year), multi-site (7 states, 70 communities), multi-
employer (10 employers) study to determine if a previously successful single-community chronic care model (Asheville Project®) could 
be replicated in multiple communities. Objective: Assess long-term clinical and financial outcomes of a chronic disease management 
model for diabetes, hypertension, and/or dyslipidemia. Design: Observational, longitudinal, retrospective, 4 year, quasi-experimental, 
multi-site, pre-post and control group study. Setting:  Ten self-insured health plans, 70 community locations across the U.S. Patients: 
Members with eligible condition meet with a “health coach”, pharmacist or health educator, on a regular basis between physician 
office visits.  Participants received reduced co-payments on disease related medications as incentive.  
Main Outcome Measures: Changes in health plan costs, changes in guideline clinical measures. Results: Financial analysis—
Participant group’s total health plan cost decreased by $2,148.83 per person per year (PPPY) diabetes, $414.37 PPPY dyslipidemia, 
$139.56 PPPY hypertension, $943.86 PPPY combining all programs.  In contrast, control group’s total health care costs increased 
$752.63 PPPY diabetes group, $520.42 PPPY dyslipidemia group, $789.95 PPPY hypertension group, and $690.26 PPPY combining all 
control group patients.  Return-On-Investment (ROI) for participant groups: $5.49:1 (diabetes), $2.36:1 (dyslipidemia), $1.86:1 
(hypertension), and $4.05:1 combined programs.  Participant’s costs decreased 25.5%, control patient’s costs increased 15.1% (net 
difference of 40.6%) over 4 year study.  Clinical analysis—(2,623 in clinical cohort):  Group not at nationally recommended clinical 
goals at baseline had statistically significant changes (improvements) in clinical measures related to diabetes, hypertension, and 
dyslipidemia.  Group at mean clinical goal at baseline continued to be at goal. Conclusion: A replication of the  Asheville Project® 
chronic care model resulted in reduced net health plan costs and improved clinical measures for diabetes, hypertension, and 
dyslipidemia, using this model that provided frequent follow-up by pharmacists/health educators, emphasis on appropriate 
medication therapy, patient education, guideline goals.  
_____________________________________________________ 
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Introduction 
A fundamental goal for improving health care delivery in the 
U.S. is to control health care costs while maintaining or 
improving quality of care.  The need to do so has increased to 
almost crisis levels.  In 2011 U.S. health care spending 
reached $2.7 trillion according to the Centers for Medicare 
and Medicaid Services, costs continue to increase and by 
2021 government spending  is projected to be nearly 50 
percent of national health expenditures.1  One approach 
proposed to help improve clinical outcomes and control, or 
reduce, health care costs is the use of chronic care models.  
One of the chronic care models that has provided evidence of 
success in improving clinical outcomes and reducing health 
care costs is the Asheville Project® model.  This model uses 
community based providers (pharmacists, health educators – 
nurses, dietitians) in a “health coach” role.  These providers 
meet with patients with chronic medical conditions between 
the patient’s routine physician office visits.  They focus on 
appropriate medication therapy, providing education on the 
benefits of improved nutrition/physical activity, and reaching 
guideline clinical goals.  This model was initially developed 
and implemented by a workgroup of the North Carolina 
Association of Pharmacists.2  Publications on this model have 
consistently shown clinical and financial improvement, 
however, the Asheville model has been limited 
geographically, technologically, and in study design.3-11  
Criticisms of the Asheville model studies have included 
questions regarding national scalability and the lack of a 
control group.  
 
In 2005, American Health Care (AHC), a pharmacist-owned 
company that provides clinical pharmacy and Population 
Health Management services, began replicating this model in 
communities across the U.S. and this study summarizes the 
outcomes of 4 years of program participation for 10 
employers in 70 communities across the U.S.  The earliest 
employer program in this study started November 2006, the 
latest April 2011, and all of the programs are ongoing at this 
time   
 
Objectives 
The objectives of this study were: 1) determine if this model 
could be replicated in multiple locations across the country, 
2) add a control group, 3) add advanced electronic patient 
record keeping/reporting technology and, 4) determine if the 
study outcomes would further validate previously published 
clinical and financial outcome improvements for individuals 
with diabetes, hypertension and/or dyslipidemia.   
 
The reason for focusing on these chronic conditions, and in 
particular a focus on appropriate medication therapy, is that 
according to the Centers for Disease Control and Prevention 
(CDC) diseases such as diabetes, heart disease and stroke are 
among the most common, costly, and preventable of all 
health problems in the U.S.12  As such, a significant portion of 
U.S. health care costs are driven by a handful of chronic 
medical conditions such as the ones listed above.  Since these 
chronic conditions are important drivers of health care costs, 
and since medication therapy is a major component of the 
treatment plan for these conditions, a focus on improving 
medication use in individuals with these conditions is a logical 
health care improvement strategy.   
 
According to a review article in the New England Journal of 
Medicine patient medication compliance/adherence in 
individuals with chronic conditions (just one of several 
important medication related issues) is “complex, labor-
intensive, and generally ineffective”.13  And as C. Everett 
Koop, M.D., former Surgeon General of the U.S., famously 
said, “Drugs don’t work in patients who don’t take them.”  
Therefore, health care models that target improvement in 
appropriate medication use are fertile ground for research.   
 
The unique aspects of this study model were: 1) voluntary 
participation, 2) community-based, 3) appointment-based, 4) 
face-to-face counseling by pharmacists and health educators, 
5) long-term, 6) reduced prescription co-payment incentives, 
7) a focus on appropriate medication therapy, 8) patient 
education, 9) adherence to evidence-based guidelines, and 
10) availability of telephonic counseling when face-to-face 
sessions were not practical. 
 
The cutoff for publication data was February 2013.  
Participants for whom face-to-face health coaching was not 
possible due to a lack of providers in some communities 
received services via telephonic management.  However, only 
3.7% were managed telephonically.  Training, tools and 
electronic patient records were developed by pharmacists at 
AHC, a pharmacist-owned company.  National guideline-
based protocols were also integrated into the electronic 
patient record.  The chronic care coaches received training in 
best practices, patient counseling and documentation.  The 
typical health coach visit averaged thirty minutes every three 
months.  Recommendations were made to physicians when 
deficiencies were identified and patients were referred back 
to their physicians when deficiencies warranted further 
assessment or when therapy changes needed to be 
considered.  In this model the physician continued to be the 
primary decision maker.  However, the individual with the 
chronic condition received additional support between 
routine physician office visits to assist them in achieving their 
treatment goals.  The cost of the program was borne by the 
employer’s self-insured health plans with the desired 
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outcome that costs for health coaching, incentives, and 
administration would be offset, or more than offset, by 
savings due to fewer adverse medical outcomes.   
 
As in the original Asheville Project the program was provided 
to self-insured health plans.  This was accomplished through 
sales/marketing calls directly to employers or through 
meetings arranged by insurance brokerage firms whose 
business it is to recommend innovative services to their 
clients.  The services were provided under a three-way 
contract between the employer, AHC, and the health 
coaches.  All of the program locations had access to a 
pharmacist for medication review even when a pharmacist 
was not the primary health coach.  All of the health coaches 
followed the same protocols and health coach fees were the 
same regardless of health coach salary, experience, or 
professional training.  The amount of the reduced 
prescription incentive varied somewhat from employer to 
employer but the typical recommended incentive was zero 
co-payment on generics and $20 off on preferred brands.  
(See Figure 1 for a schematic of the Asheville model published 
as part of an AHRQ Innovations Profile in 2012.) 14 
 
AHC’s role was to: 1) locate and contract with employers 
willing to pay for the services, 2) provide a web-based, 
secure, electronic record of care, 3) identify the eligible 
population,  4) inform eligible individuals of the option of 
having a health coach, 5) inform eligible individuals of the 
intended health benefits of the program, 6) administer 
financial incentives, 7) outline requirements for routine 
laboratory testing and follow-up with physician, 8) import 
medical and prescription claims data into the electronic 
record on a monthly basis, 9) provide standardization of care 
through incorporation of guidelines of care into the electronic 
record to direct the health coach-patient interaction, 10) 
identify deficiencies in care, and 11) generate outcomes 
reports of clinical and financial results for the 
employer/health plan on a regular basis.  Six of the items 
above (1,2,8,9,10 and 11) were enhancements to the original 
Asheville model, as was the addition of a control group to the 
study.  A weakness of the original Asheville model was the 
lack of a mechanism for sales/marketing of the service.  It 
started simply as a pilot program with one employer.  Its 
success led to the desire to create a business model which 
included the need for sales/marketing.  Another need 
following the pilot programs was an electronic record of care 
for health coaches to use to document their visits 
consistently. The charts in the original pilot program were 
traditional paper charts.  Another enhancement to the 
original program was to incorporate each patient’s medical 
and prescription claims (historical and current) into an 
electronic record.  This allowed identification of gaps in care 
(e.g. patient not seeing physician, appropriate laboratory 
tests not being ordered, frequent emergency department 
visits).  This claims data was provided by each employer’s 
Pharmacy Benefits Management company and their Third 
Party Administrator on a monthly basis and this data was 
incorporated into each patient’s individual electronic record.  
There was also a need to standardize care and incorporate 
national guideline standards into the process so that whether 
it was a pharmacist in North Carolina, or California, the same 
standards would apply.  One of the biggest deficiencies in the 
Asheville Project program was the need to collect, collate, 
and analyze data manually.  This is now incorporated into the 
electronic record of care.   
 
Methods 
Main outcome measures: 
• Changes in health plan costs over time for program 
participants and for a control group of patients who 
did not participate. 
Secondary outcome measures: 
• Changes in clinical measures over time [Table 1].  
This was paired data and the baseline and most 
recent data for the population were normally 
distributed; hence, paired T-test was conducted.   
• Other secondary measures included several 
qualitative measures based on guideline 
recommendations for lifestyle changes [Figures 2a, 
2b].  Mean baseline values were compared with the 
mean of the latest values (non- paired data).     
 
Design:  This study was an observational, longitudinal, 
retrospective, 4 year, quasi-experimental, multi-site, pre-post 
and control group cohort analysis.  It examined clinical and 
financial outcomes for individuals who had the option under 
their health plan to enroll in a chronic disease program for 
diabetes, hypertension, and/or dyslipidemia.  The financial 
control group was composed of individuals with an eligible 
condition who did not participate in the program.  The 
original and ongoing aspects of the study were approved by 
the Investigational Review Board of Mission Hospitals. 
 
Setting:  Ten self-insured employers (7 states, 70 locations) 
agreed to cover the program under their health plan benefits 
and it was offered to health plan members with any of the 
eligible conditions.  The program provided participants a 
personal health coach, a pharmacist or health educator 
(nurse, dietitian) who were to meet with them at least 
quarterly, but visits could be as often as once a month 
depending on the patient’s needs.  All program participants 
had access to a pharmacist for medication assessment.  
Eligibility for the program was determined through medical 
and prescription claims.  Participation was voluntary, 
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however, participants received incentives (reduced 
prescription co-payments on disease related 
prescriptions/supplies). 
 
Methodology:   Health care professionals used an electronic 
record to document patient care visits; a proprietary, secure 
web-based communication portal that created an integrated 
medical profile.  The record provided continuously updated 
medical and pharmacy claims data, clinical data, health coach 
visit documentation and also identified gaps in care.  It was 
also the source of data for reports on clinical and financial 
outcomes .15  
 
Health plan members with diabetes, hypertension, and/or 
dyslipidemia were offered the option of enrolling in a 
voluntary “health coach” program to assist them in the 
management of their condition.  By enrolling they agreed to 
meet face-to-face with a health coach in their community on 
a regular basis.  This could be as often as once-a-month if in 
the judgment of the health coach the individual needed that 
level of interaction.  Participation qualified the individual for 
reduced prescription co-payments on medications for their 
chronic condition.  The same standard protocols were 
followed by the health coach providers, regardless of their 
professional background, and the protocols mirrored the 
recommendations of the relevant national guidelines relative 
to appropriate medication therapy, monitoring, assessment, 
and goal setting.  The guidelines used were from the 
American Diabetes Association, Joint National Committee, 
and National Cholesterol Education Program.16,17,18  The same 
national guideline standards were also the basis of the 
original Asheville Project provider training. 
 
The diabetes group’s data extended over 4 years and the 
hypertension and dyslipidemia group’s data extended over 3 
years.  This study reports changes over time in total health 
plan costs (financial analysis) and clinical values (clinical 
analysis).  Total health plan costs were defined as the sum of 
all medical claims and all prescription claims paid by the 
employer’s self-funded health insurance plan for health plan 
members with an eligible condition.  The study does not 
examine patient’s out-of-pocket costs.  It looks at health care 
costs strictly from the perspective of the costs to the self-
funded health plans.  Plan members with an eligible condition 
who did not enroll in the program were the financial control 
group.  
 
Three basic financial comparisons are made: 1) changes in 
health plan costs for participants over time (self-as-control), 
2) changes in health plan costs for non-participants (self-as-
control), and 3) a comparison of participant costs and non-
participant costs over time (control group comparison).   In 
addition, return-on-investment (ROI) analyses are provided. 
 
Return-On-Investment (ROI) was calculated by dividing gross 
savings (relative to baseline costs) by total program costs.  
Program costs included all administrative fees, health coach 
fees, reduced prescription co-payment cost and additional 
laboratory testing.   
 
This study reports on changes in clinical values over time for 
participants (self-as-control) using paired data.  Clinical data 
on non-participants was not available so the report does not 
provide a control group for the clinical data. 
 
Inclusion criteria:   1) covered plan member of a participating 
employer, 2) had diabetes, hypertension, and/or 
dyslipidemia, 3) enrolled and had at least one health coach 
encounter and, 4) were enrolled for a minimum of a year 
(and up to four years).  
 
To be included in the participant group financial analysis, in 
addition to the above inclusion criteria, plan members also 
needed to have both a complete year of baseline (historical) 
medical and prescription claims data and at least one 
complete year of medical and prescription claims for a 
subsequent study year.  In order to be included in the control 
group financial analysis, non-participant individuals needed to 
meet the same criteria as the participant financial group, but 
did not enroll in the program and had no health coach visits.  
 
To be included in the clinical analysis participants needed to 
be a plan member, have an eligible condition, participant for 
at least a year, plus have at least a baseline clinical value and 
a subsequent value.  Baseline was defined as the value 
closest to the first health coach visit within a + 3 month 
window of their first visit.  Most recent value was defined as 
the last follow-up value documented in the electronic record.  
 
Exclusion criteria:  Individuals (participants and non-
participants) were excluded from the financial analysis if they 
did not have a complete baseline year of financial data and at 
least one complete subsequent year of financial data.  
Individuals were also excluded from the participant and non-
participant (control) group financial analysis if they had high 
cost events (greater than $12,000) that were unrelated to 
their program health condition (e.g. cancer, spine surgery, 
HIV).  If this fell in their baseline year they were excluded 
from the financial analysis completely.  If the unrelated high 
cost event fell in a subsequent year their financial data was 
excluded for only that year and these criteria were applied 
equally to participant and non-participant (control) groups.  
Individuals were excluded from the clinical group if they were 
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missing a baseline value, a follow-up value, or both (paired 
data was required). 
 
Financial data was aggregated based on enrollment dates.  
Each individual’s baseline year was determined by their 
individual enrollment date.  For example, everyone’s first 
year of participation was aggregated as the “first program 
year” regardless of when they enrolled.  An adjustment for 
inflation was applied using an inflation factor published by 
Pricewaterhouse Coopers LLP 
(http://www.pwc.com/us/en/health-industries/behind-the-
numbers). 
 
Data Analysis 
In this retrospective analysis baseline clinical outcomes were 
compared to the most recent outcomes using a paired T-test 
or Wilcox Rank sum test as appropriate for data distribution 
(parametric or non-parametric).  The normality of the data 
distribution was tested to examine skewness and kurtosis.  
Statistical significance was set at p<0.05. Analyses were 
performed using STATA 10.1 Statistics/Data Analysis 
software.  
 
Disease state goals were established based on national 
guidelines [American Diabetes Association (ADA)16 and 
American Association of Clinical Endocrinologists (AACE) for 
diabetes program, JNC-7 and American Heart Association for 
Hypertension (AHA) program, and National Cholesterol 
Education Program (NCEP), ATP III, AACE and AHA for 
dyslipidemia program.17-20   
 
Patients:  The average age of the participant group was 54.8 
years and the average age for individuals in the non-
participant group was 56.4 years.  Sixty-five percent of the 
participant group were female and 54% of the non-
participant group were female.   
 
Results 
Financial results:  Over the time period of the study the 
participant group’s total health plan cost decreased by an 
average of $2,148.83 PPPY for the diabetes group, $414.37 
PPPY for the dyslipidemia group, $139.56 PPPY for the 
hypertension group, and $943.86 PPPY when combining all 
programs.  In contrast, over the same time period the non-
participant (control) group experienced an increase in costs 
by an average of $752.63 PPPY, $520.42 PPPY, $789.95 PPPY, 
and $690.26 PPPY respectively for diabetes, dyslipidemia, 
hypertension, and combined groups.  
 
Participant’s health plan costs decreased 25.5% and non-
participant control patient’s costs increased by 15.1% (a delta 
of 40.6%) over the 4 year time period of the study. [Table 2]  
Total emergency department and hospital visits decreased by 
32.8% in the participant group and increased by 8.7% in the 
non-participant group. 
 
ROI for participant groups was $5.49:1 for diabetes, $2.36:1 
for dyslipidemia, $1.86:1 for hypertension, and $4.05:1 for all 
programs combined (including all program costs). ROI was 
calculated by dividing the gross cost savings relative to 
baseline by the total of all program costs.  Program costs 
included all administrative fees, health coach fees, reduced 
prescription co-payment cost, and any additional laboratory 
testing or physician office visits that resulted from the 
program interventions.   
 
Clinical results:  Clinical data was examined to address two 
questions:  1) Did the group who were not at goal at baseline 
improve?  2) Did the group who were at goal continue to be 
at goal?   
 
The group who were not at goal (based on guidelines for their 
condition(s) at the time they entered the program were 
examined.  The most recent clinical results were statistically 
different   (improved) from baseline (p-value <0.05) for all 
measures; A1C, SBP, DBP, LDL, HDL, TC, TG, and TC/HDL ratio.  
[Table 1]   
 
Notable clinical findings [Table 1] include:  Diabetes group:  
A1C decreased by an average of 0.58, SBP decreased by an 
average of 10.2 mm/Hg, DBP decreased by an average of 7.2, 
LDL decreased by an average of 17.9mg/dL, HDL increased by 
an average of 1.8mg/dL, TG decreased by an average of 
45.3mg/dL, and TC/HDL ratio improved from an average of 
6.20 to 5.23.  Hypertension group:  SBP decreased by an 
average of 17.0mmHg and DBP decreased by an average of 
12.4. Dyslipidemia group:  SBP decreased by an average of 
16.0mmHg, DBP decreased by an average of 12.8, LDL 
decreased by an average of 16.0mg/dL, HDL increased by 
average of 2.1mg/dL, TG decreased by an average of 
43.5mg/dL, TC decreased by an average of 17.0mg/dL, and 
TC/HDL ratio improved from an average of 6.43 to 5.73.  
 
Lifestyle/behavior change improvements were observed in all 
participant groups. [Figure 2a, 2b] 
 
The group who were at goal at the time they entered the 
program were examined to determine if they remained at 
goal.  End of study averages for the group who were already 
at goal at baseline:  Diabetes group: A1C 6.6% (goal <7%), 
blood pressure 120/73mmg/Hg (goal <130/80), LDL 79mg/dL 
(goal <100), HDL 52mg/dL (goal >40), TG 112mg/dL (goal 
<150), TC 156mg/dL (goal <200), TC/HDL 3.55 (goal <5).  
Dyslipidemia group: LDL 99mg/dL (goal <130), HDL 58mg/dL 
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(>40), TG 103mg/dL (goal <150), TC 171mg/dL (goal <200), 
TC/HDL 3.55 (goal <5).  Hypertension group: blood pressure 
122/75mm/Hg (goal <140/90). 
 
Discussion 
This large, multi-site, multi-year, control group study looked 
at the financial and clinical impact of a community based 
chronic care model for individuals with diabetes, 
hypertension, and/or dyslipidemia.  This model uses “health 
coaches” (pharmacists, health educators) who meet on a 
regular basis with patients between normal physician office 
visits.  All participants had access to a pharmacist for 
medication review, clinical assessment, patient education, 
and recommendations to other health care providers. 
 
A notable finding of the study was that the group not at 
clinical goal upon entering the program experienced 
statistically significant improvements on all clinical measures.  
And the group of patients who were already at clinical goal 
upon entering the program continued to be at goal on all 
clinical measures at the end of the 4 year study period.   
 
Over the 4 year study period participant’s health care costs 
decreased by 25.5%, whereas non-participant (control group) 
health care costs increased by 15.1%.  Therefore, the 
potential positive impact of the program was a savings of 
40.6%.  It is notable that both groups had very similar 
historical (baseline) health plan costs.  Baseline costs for the 
participant group was $4,648 PPPY vs. $4,753 PPPY for the 
non-participant group.  [Table 2] 
 
Return-On-Investment (ROI) calculation, which takes into 
account all the costs of the program, for 1,314 participants 
with diabetes was $5.49:1 (for every dollar spent on the 
program $5.49 was saved).  ROI for 730 dyslipidemia 
participants was $2.36:1, and for 1,488 hypertension 
participants was $1.86:1.  [Table 2]   This is the first study of 
the Asheville model using a financial control group and it is 
noteworthy that the savings experience was very similar to 
the earlier non-control group studies which provides further 
validation of the earlier studies.  The Asheville Project 
published a PPPY savings average for the diabetes group of 
$1,200 - 1,872 PPPY (vs. $2,901 PPPY in this current study).  
And an Asheville Project savings of $628 PPPY was reported in 
their hypertension/dyslipidemia group (vs. $931 PPPY in this 
current study).3,5 
 
Total emergency department and hospital visits decreased by 
32.8% in the current participant group, whereas there was an 
increase of 8.7% in the non-participant control group.   
 
Successful control of health plan costs is often viewed as 
simply decreasing the rate of increase in health plan costs.  
However, this model has not simply decreased the rate of 
increase, it has consistently decreased costs in multiple 
studies for thousands of patients over a period of more than 
15 years. 
 
There are similarities between this program and Medication 
Therapy Management (MTM).  Both are models that use face-
to-face encounters between patients and pharmacists.  Both 
focus on appropriate medication use, adjustments in 
medication therapy and improving care.  A primary difference 
is that this current model has regular ongoing sessions with 
the patients, whereas MTM visits are typically once a year.  
The current model could be viewed as “frequent” MTM and, 
therefore, has the potential to be more impactful than the 
current “infrequent” MTM model.  This model also differs in 
that it typically provides services for younger individuals who 
are currently in the workforce, as opposed to the typical 
retired Medicare recipient.  The implications of the latter are 
that there is potentially more benefit the earlier in life 
someone receives better management of their chronic 
medical condition. 
 
Although this study exclusively used self-insured plans the 
results are applicable to other health payment systems.  
Whether the payment system is managed care, commercial 
insurance, Accountable Care Organizations (ACO) or Medical 
Home models, someone is paying for the poor medical 
outcomes of these chronic conditions.  Whoever is incurring 
these costs should be interested in models of care that 
effectively lower their costs.  The authors believe this model 
could integrate well with ACO efforts and Medical  
Home models since it is: 
1) Community-based 
2) Paid for by health plans 
3) Saves more than it costs 
4) Addresses patient needs between routine physician 
office visits  
5) Improves patient care without requiring physician 
offices to invest additional time and resources 
6) Supplements, rather than replaces, health care 
services already being provided 
7) Takes advantage of underutilized community health 
resources (pharmacists and health educators) 
8) And for pharmacists, takes advantage of their broad 
geographic distribution, a potentially significant 
access point for public health improvement 
  
This potential is largely untapped, however, this study 
indicates that when pharmacists and health educators are 
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paid to provide “health coach” services, objective clinical 
measures improve and there is a net health plan savings. 
 
Limitations 
Lack of a randomization process is a limitation of this study.  
Participation was voluntary and there may have been 
differences between those that enrolled vs. those that did 
not enroll.  Enrollees may have been more motivated to 
pursue treatment success than non-enrollees.  Selection bias, 
therefore, may be a study limitation.   
 
There were two potential confounding variables related to 
enrollment.  On the one hand the reduced prescription co-
payment incentive may have motivated individuals with more 
medical issue (those taking more medications) to enroll and 
result in a participant group with a greater potential for cost 
savings than their non-participant peers.  On the other hand 
the reduced prescription co-payment incentive would not be 
a strong incentive for individuals who were failing to take 
their medications and, because of this, would be at higher 
risk for increased medical costs.  This could have resulted in a 
non-participant group with a greater potential for cost 
savings than their participant peers.  These two factors, 
therefore, could have offsetting effects.    However, this study 
was unable to assess the specific impact of each factor.  The 
non-participants were slightly older on average than the 
participant group (56.4 years vs. 54.8 years) and the non-
participant group had a11% higher percentage of males than 
the participant group (46% vs. 35%). These differences could 
have influenced the results of the analysis.  It was 
encouraging, therefore, that in spite of these differences both 
groups had virtually identical baseline historical health plan 
costs.  The average annual historical health plan cost average 
was $4,753 PPPY for non-participants and $4,648 PPPY for 
participants.  [Table 2]  The participants were not the more 
costly group historically and, therefore, the reduction in costs 
they experienced does not appear to be attributable to a 
greater cost reduction potential at baseline in the participant 
group.   
 
Of particular concern with a study of changes in health plan 
costs over time is the potential for regression-to-the-mean, 
the chance that decreases in costs were due to 
improvements that would have occurred without the 
program interventions because, on average, a bad year would 
be followed by a better year.  A related factor being that 
individuals who had just experienced a bad year may have 
been more motivated to enroll than someone who had a 
good year, another potential source of selection bias.  Having 
the control group’s costs be virtually identical at baseline, 
however, speaks against this “bad year” scenario since the 
actual observation was that participants did not have a worse 
baseline year financially than the non-participants.  
Additionally, a possible factor speaking against regression-to-
the-mean was the length of the study (4 years).  Chronic 
conditions tend to get worse over time rather than better.  
Therefore, regression-to-the-mean is less of a factor as the 
length of a study increases and improvements continued to 
be sustained, which was the observation in this study.    
 
Additional limitations were the lack of availability of clinical 
data on the non-participant group, missing and/or 
unreported clinical data, as well as the limitations (and 
errors) inherent in the claims processing world.   
 
Having a control group, a study population of several 
thousand patients, application of the same inclusion and 
exclusion criteria to both groups, and a study period of 4 
years mitigate some of the above limitations.  However, this 
study was unable to account for all potential variables or to 
determine which of the basic program elements; health 
coaching, incentives, standardized protocols, or the use of an 
electronic record with integrated guideline care processes 
were responsible for all, or part, of the observed 
improvements.  It can only be stated that the combination of 
these elements resulted in the successful outcomes 
observed. 
 
Conclusion 
This study demonstrates that the Asheville model is replicable 
in other communities.  It also adds further evidence that this 
chronic care model which uses pharmacists and health 
educators to focus on improving medication therapy, patient 
knowledge and goal achievement, results in clinical 
improvement and lower overall health care costs for 
individuals with diabetes, dyslipidemia, and/or hypertension.   
 
It is possible to improve care and reduce health care costs for 
individuals with diabetes, dyslipidemia, and/or hypertension 
using a chronic care model.  What is lacking in the U.S. 
healthcare system are widespread, efficient, affordable 
chronic care approaches which assure that medications are 
being used effectively and that lifestyle changes are actually 
taking place.  There is growing evidence that this particular 
chronic care model is one such approach. 
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Table 1: Clinical Results: Baseline vs. Most Recent value for individuals who were not at goal at baseline 
  
Clinical 
Metrics*,** Number 
 
Age 
(yr) 
 
Male/Female 
(#) 
Baseline 
Average** 
Most Recent 
Average** Change** p-value*** Confidence Interval 
DIABETES MELLITUS 
A1C≥7 554 50.43 215/339 8.45 7.87 -0.58 <0.0001 .4472057    .7130831 
SBP≥130 549 53.81 260/289 141.99 131.77 -10.22 <0.0001 8.806705    11.62317 
DBP≥80 493 51.02 228/265 85.16 78.00 -7.16 <0.0001 6.285761    8.034726 
LDL≥100 339 50.98 111/228 126.92 108.99 -17.93 <0.0001 14.64035    21.22868 
HDL<40 297 51.90 168/129 33.22 35.00 +1.78 <0.0001 1.021244    2.540372 
TG≥150 308 52.65 122/186 239.06 193.81 -45.25 <0.0001 32.37279    58.10773 
TC≥200 166 50.96 39/127 227.25 200.64 -26.61 <0.0001 19.83242    33.38445 
TC/HDL≥5 114 50.37 44/70 6.20 5.23 -0.97 <0.0001 .6598332    1.285168 
DYSLIPIDEMIA 
SBP≥130 74 56.45 27/47 148.22 132.24 -15.98 <0.0001 12.67727    19.26868 
DBP≥80 41 51.71 20/21 94.12 81.37 -12.75 <0.0001 9.921684    15.59051 
LDL ≥ 130 92 50.15 20/72 160.41 144.40 -16.01 <0.0001 8.509113    23.50828 
HDL<40 76 52.00 45/31 33.40 35.48 +2.08 <0.0363 .1369637    4.031457 
TG≥150 131 52.22 44/87 241.45 197.98 -43.47 0.0001 22.48157    64.46499 
TC≥200 142 51.30 35/107 235.71 218.74 -16.97 <0.0001 10.65376    23.2899 
TC/HDL≥5 43 50.09 16/27 6.43 5.73 -0.70 0.001 .2969621    1.093502 
HYPERTENSION 
SBP≥140 133 54.86 42/91 150.57 133.53 -17.04 <0.005 14.24011    19.83508 
DBP≥90 186 51.70 108/78 94.40 81.96 -12.44 <0.005 10.99624    13.88548 
 
 *Clinical Metrics column shows “not at goal” parameter (e.g. Guideline A1c goal is <7%, so “not at goal” parameter is  ≥7) 
**Values:  A1c (%), SBP/DBP (mm/Hg), LDL (mg/dL), HDL (mg/dL), TG (mg/dL), TC (mg/dL), TC/HDL (ratio) 
 ***Statistically significant: p-value <0.05 
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Table 2: Financial Results 
 
*PPPY = per person per year 
**Net savings: Includes all program and incentive costs  
***ROI = return-on-investment 
    N/A: Not applicable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Program 
# of 
Health 
Plans 
Study 
Time 
Period 
Number of 
Individuals 
Baseline 
Avg. 
PPPY* 
Health 
Plan Costs 
Total Net Plan 
Savings/(Loss) 
Relative to 
Baseline 
Over Study 
Period** 
Change in 
Total 
Health 
Plan 
Spend 
Relative to 
Baseline  
 Savings 
(or 
Loss)  
PPPY avg. 
Savings 
(Participan
t relative 
to Non-
participant 
control 
group) 
PPPY avg. 
Spread/Delta                                          
(Participant 
savings plus 
Non-
participant 
control group 
loss) 
ROI*** 
Participants 
relative  
to their 
baseline)  
DIABETES MELLITUS 
Participants 10 48 months 1314 $7,716.19 $2,823,565.60 -31.7% $2,148.83 
+$2,901.46 43.4% 
$5.49:1 
Non-Participant 
Controls 10 48 months 2451 $7,287.43 ($1,844,691.53) +11.7% ($752.63) N/A 
DYSLIPIDEMIA 
Participants 10 36 months 730 $4,192.89 $302,489.63 -17.2% $414.37 
+$934.79 30.6% 
$2.36:1 
Non-Participant 
Controls 10 36 months 2931 $3,857.10 ($1,525,359.10) +13.4% ($520.42) N/A 
HYPERTENSION 
Participants 10 36 months 1488 $2,161.74 $207,668.77 -14.0% $139.56 
+$929.51 35.3% 
$1.86:1 
Non-Participant 
Controls 10 36 months 3460 $3,716.33 ($2,733,218.01) +21.3% ($789.95) N/A 
TOTALS 
All Programs/All 
Years 
(Participants 
Population) 
10 36-48 months 3532 $4,648.00 $3,333,723.90 -25.5% $943.86 
+$1,634.12 40.6% 
$4.05:1 
All Programs/All 
Years (Non-
Participant 
Control 
Population) 
10 36-48 months 8842 $4,753.00 ($6,103,268.64) +15.1% ($690.26) N/A 
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Figure 1:  Diagram of Improved Asheville Chronic Care Model 
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Figure 2a: Lifestyle/Behavior Changes 
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Figure 2b: Lifestyle/Behavior Changes (Continued) 
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